Oral Semaglutide
OASIS 4
Novo Nordisk · Phase 3 · Completed · Enrollment 307
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Oral semaglutide 25 mg | 95 participants | 63 participants | 36 participants | n/r | 0 |
| Oral semaglutide placebo | 19 participants | 6 participants | 9 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.